SOM3355

Reclutando

ACERCA DE:

PATROCINADOR

SOM Biotech

PARTICIPANTES

129

El objetivo principal de este ensayo es estudiar la eficacia y seguridad de SOM3355 en pacientes con la enfermedad de Huntington (EH). El SOM3355, que se ha utilizado para la hipertensión, se estudiará en este ensayo de fase 2b para establecer si ayuda con la corea en la EH. Un grupo recibirá el fármaco (dos dosis y uno de placebo) por vía oral dos veces al día durante 12 semanas. Se reclutarán 129 participantes.

Catherine Scart presenta las novedades
del ensayo clínico SOM3355

Edades elegibles para el estudio

21 años o más (adulto)

Sexos elegibles para el estudio:

Todos

Acepta voluntarios sanos:

No

CRITERIOS DE INCLUSIÓN

  • Pacientes con un diagnóstico de enfermedad de Huntington determinado por un experto en trastornos del movimiento y confirmado por un número de repeticiones CAG del gen HTT ≥36.
  • Puntuación total de corea máxima (TMC) de la UHDRS ≥10.
  • Capacidad funcional total UHDRS (TFC) ≥7.
    Capaz de caminar de forma independiente o con una ayuda mínima.
  • Las mujeres en edad fértil deben utilizar un método anticonceptivo eficaz médicamente aceptado y no deben estar amamantando.
  • En opinión del Investigador, el paciente debe tener el apoyo adecuado para cumplir con todos los requisitos del estudio.
  • Ser capaz y estar dispuesta a dar su consentimiento informado por escrito.

CRITERIOS DE EXCLUSIÓN

  • Inicio de los síntomas de la EH antes de los 21 años (formas juveniles de EH).
  • Pacientes con EH que presentan acinesia rígida.
  • Uso de otros inhibidores de la VMAT2 como tetrabenazina, deutetrabenazina o valbenazina; y uso de otro tratamiento anticoreico como cualquier neuroléptico, o amantadina, memantina, riluzol.
  • Pacientes que hayan sufrido una depresión grave o un intento de suicidio en los últimos 5 años.
  • Enfermedad psiquiátrica grave no tratada o infratratada, como ideación o comportamiento suicida activo o depresión.
  • Pacientes con antecedentes de hipotensión, bradicardia o hipotensión ortostática, o que la padecen actualmente.
  • Pacientes con hipertensión ya tratados con más de 2 fármacos antihipertensivos.
  • Otras enfermedades activas clínicamente significativas que puedan interferir con la realización del estudio, contraindicar el tratamiento del estudio, poner al paciente en riesgo durante el ensayo o comprometer su participación en el mismo.
  • Cualquier anomalía grave y significativa en el electrocardiograma (ECG), o un historial conocido de síndrome de QTc largo.
  • Pacientes con insuficiencia hepática grave, o con insuficiencia renal grave, o con cualquier otra anomalía significativa en la exploración física o en los resultados del laboratorio clínico que, a juicio del investigador, no sea compatible con la participación en el estudio o represente un riesgo para el paciente durante el mismo.
  • Mujeres embarazadas o en periodo de lactancia, o que pretendan quedarse embarazadas durante el periodo del estudio.
  • Pacientes con alergia en proceso de desensibilización, con psoriasis conocida o con una alergia/hipersensibilidad conocida a cualquier ingrediente de la medicación del ensayo o del placebo.
  • Antecedentes de abuso de alcohol o sustancias en los 12 meses anteriores.
  • Pacientes que participan en cualquier otro estudio, y el uso de cualquier terapia de investigación.

PAÍSES

SITIOS

FRANCIA

TRIAL SITE:
Centre Hospitalier Universitaire Angers

Address: Angers, France

TRIAL SITE:
CHU Hôpital Henri Mondor (APHP)

Address: Créteil, France

TRIAL SITE:
Hôpital Roger Salengro – CHU Lille

Address: Lille, France

TRIAL SITE:
Hopital de Hautepierre

Address:Strasbourg, France

TRIAL SITE:
Hôpital Purpan – CHU Toulouse

Address:Toulouse, France

ALEMANIA

TRIAL SITE:
Charité – Universitätsmedizin Berlin

Address: Berlin, Germany

TRIAL SITE:
George Huntington Institut

Address: Münster, Germany

TRIAL SITE:
Hospital of University of Ulm

Address: Ulm, Germany

TRIAL SITE:
kbo-Isar-Amper-Klinikum

Address: Kölner Pl. 1/Haus 7, 80804 München, Germany

ITALIA

TRIAL SITE:
IRCCS Istituto delle Scienze Neurologiche di Bologna

Address: Bologna, Italy

TRIAL SITE:
Azienda Ospedaliera Universitaria Federico II

Address: Napoli, Italy

TRIAL SITE:
IRCCS Casa Sollievo della Sofferenza

Address: Roma, Italy

TRIAL SITE:
Sant’Andrea University Hospital

Address: Roma, Italy

POLONIA

TRIAL SITE:
Krakowska Akademia Neurologii Sp. z o.o.

Address:Kraków, Poland

TRIAL SITE:
Indywidualna Praktyka Lekarska Daniel Zielonka

Address: Poznań, Poland

ESPAÑA

TRIAL SITE:
Hospital de la Santa Creu i Sant Pau

Address: Barcelona, Spain

TRIAL SITE:
Hospital Universitario de Cruces

Address: Bilbao, Spain

TRIAL SITE:
Hospital Universitario de Burgos

Address:Burgos, Spain

TRIAL SITE:
Hospital Ramón y Cajal

Address: Madrid, Spain

SUIZA

TRIAL SITE:
Universitaetsspital Bern – Inselspital

Address: Bern, Switzerland

REINO UNIDO

TRIAL SITE:
Cambridge University Hospitals NHS Foundation Trust Addenbrooke’s Hospital

Address: Cambridge, United Kingdom

TRIAL SITE:
NIHR Wellcome Trust Manchester Clinical Research Facility

Address:Manchester, United Kingdom

TRIAL SITE:
Oxford University Hospitals NHS Foundation Trust

Address: Oxford, United Kingdom

new FB feed (19)

dictionary:

SNP-single nucleotide polymorphisms

a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.

 
new FB feed (19)

dictionary:

at risk

You do not know if you carry the genetic mutation for HD gene 

 
new FB feed (19)

dictionary:

TFC-total functional capacity

A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity. 

 
new FB feed (19)

dictionary:

Double-blinded

 means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.

new FB feed (19)

dictionary:

Open label

A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.

new FB feed (19)

dictionary:

Gene therapy

a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.

new FB feed (19)

dictionary:

UHDRS- Unified Huntington Disease Rating Scale

A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD

new FB feed (19)

dictionary:

CAG repeat

The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD

new FB feed (19)

dictionary:

Wild-type

the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein

new FB feed (19)

dictionary:

Tolerabilty

How well a person can handle a treatment without having serious or uncomfortable side effects.

new FB feed (19)

dictionary:

Striatum

Part of the brain that  coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.

new FB feed (19)

dictionary:

Randomized allocation

A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

new FB feed (19)

dictionary:

Radioligand

a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity

new FB feed (19)

dictionary:

Protein

Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.

new FB feed (19)

dictionary:

Premanifest / Prodromal

Prior to onset or diagnosis of movement symptoms.

new FB feed (19)

dictionary:

Placebo

A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.

new FB feed (19)

dictionary:

PK - Pharmacokinetics

The movement of drugs through the body

new FB feed (19)

dictionary:

PD - Pharmacodynamics

The body’s biological response to drugs

new FB feed (19)

dictionary:

PET scan

Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.

new FB feed (19)

dictionary:

Neuron

Brain cells that store and transmit information

new FB feed (19)

dictionary:

MRI

Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones 

new FB feed (19)

dictionary:

mHTT

Mutant huntingtin protein. The protein produced by the faulty HD gene.

new FB feed (19)

dictionary:

Manifest

after HD diagnosis, or when symptoms are already showing

new FB feed (19)

dictionary:

Longitudinal study

A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once

new FB feed (19)

dictionary:

HTT

one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15

new FB feed (19)

dictionary:

fMRI

functional MRI:As with MRI, a technique using powerful magnetic fields  but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes

new FB feed (19)

dictionary:

CSF - cerebrospinal fluid

A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

new FB feed (19)

dictionary:

Efficacy

A measure of whether a treatment works or not

new FB feed (19)

dictionary:

ASO(Antisense oligonucleotides)

A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

new FB feed (19)

dictionary:

Biomarker

a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable

new FB feed (19)

dictionary:

BDNF

Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.

new FB feed (19)

dictionary:

Allele

one of the two copies of a gene

new FB feed (19)

dictionary:

Plasma

Liquid component of the blood.

new FB feed (19)

dictionary:

Gene

The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.

new FB feed (19)

dictionary:

Phase

Clinical trial phases are different stages of research that assess the safety and effectiveness of a new medical treatment or intervention in humans.

Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.